DNA damage response markers are differentially expressed in BRCA-mutated breast cancers

Breast Cancer Research and Treatment

Volumn 150, Issue 1, 2015, Pages 81-90

  Aleskandarany, Mohammed ^a,b   Caracappa, Daniela ^a,c,d   Nolan, Christopher C ^a   Macmillan, R Douglas ^b   Ellis, Ian O ^a   Rakha, Emad A ^a   Green, Andrew R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MENOUFIA UNIVERSITY   (Egypt)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

BRCA mutated breast cancers; DNA damage response; DNA repair

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; KU ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROGESTERONE RECEPTOR; PROTEIN P53; RAD51 PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SIZE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOTIC FREQUENCY; NOTTINGHAM PROGNOSTIC INDICATOR; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PLEOMORPHISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TUBULE FORMATION; VASCULAR INVASION; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; MUTATION; NEOVASCULARIZATION (PATHOLOGY); OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; TUMOR VOLUME;

BIOMARKERS, TUMOR; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA DAMAGE; DNA REPAIR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASM GRADING; NEOVASCULARIZATION, PATHOLOGIC; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR BURDEN;

EID: 84925513470     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3306-6     Document Type: Article

References (47)

1. Wu P-E, Shen C-Y (2011) ‘Hide-then-hit’ to explain the importance of genotypic polymorphism of DNA repair genes in determining susceptibility to cancer. J Mol Cell Biol 3(1):59–65
2. Polo SE, Jackson SP (2011) Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev 25(5):409–433
3. Cheung-Ong K, Giaever G, Nislow C (2013) DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol 20(5):648–659
4. Hosoya N, Miyagawa K (2014) Targeting DNA damage response in cancer therapy. Cancer Sci 105(4):370–388
5. Morales J, Li L, Fattah FJ, Dong Y, Bey EA, Patel M, Gao J, Boothman DA (2014) Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr 24(1):15–28
6. Gildemeister OS, Sage JM, Knight KL (2009) Cellular redistribution of Rad51 in response to DNA damage: novel role for Rad51C. J Biol Chem 284(46):31945–31952
7. Gudmundsdottir K, Ashworth A (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25(43):5864–5874
8. Tutt A, Ashworth A (2002) The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 8(12):571–576
9. Virag L (2005) Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies. Curr Vasc Pharmacol 3(3):209–214
10. Westermark UK, Reyngold M, Olshen AB, Baer R, Jasin M, Moynahan ME (2003) BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks. Mol Cell Biol 23(21):7926–7936
11. Forget AL, Kowalczykowski SC (2010) Single-molecule imaging brings Rad51 nucleoprotein filaments into focus. Trends Cell Biol 20(5):269–276
12. Skorokhod OM, Kravchuk IV, Teleheiev HD, Maliuta SS (2006) Role of Ku protein in normal and cancer cells. Ukr Biokhim Zh 78(5):5–15
13. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847
14. McCarty KS Jr, McCarty KS Sr (1984) Histochemical approaches to steroid receptor analyses. Semin Diagn Pathol 1(4):297–308
15. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32
16. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302–2310
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16):1180–1184
18. Edlich RF, Winters KL, Lin KY (2005) Breast cancer and ovarian cancer genetics. J Long Term Eff Med Implants 15(5):533–545
19. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, Milner J, Brown LA, Hsu F, Gilks B et al (2003) EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115(5):523–535
20. Korkola J, Gray JW (2010) Breast cancer genomes––form and function. Curr Opin Genet Dev 20(1):4–14
21. van der Groep P, Bouter A, van der Zanden R, Siccama I, Menko FH, Gille JJ, van Kalken C, van der Wall E, Verheijen RH, van Diest PJ (2006) Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 59(6):611–617
22. Chappuis PO, Nethercot V, Foulkes WD (2000) Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18(4):287–295
23. Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat JP, Longy M, Guinebretiere JM, Sauvan R, Noguchi T et al (1998) Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 58(8):1588–1592
24. Kleer CG (2009) Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions. Arch Pathol Lab Med 133(11):1822–1825
25. Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25(43):5846–5853
26. Mangia A, Malfettone A, Simone G, Darvishian F (2011) Old and new concepts in histopathological characterization of familial breast cancer. Ann Oncol 22(Suppl 1):i24–i30
27. Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM (2010) Upregulation of poly (ADP-Ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 1(8):812–821
28. De Summa S, Pinto R, Pilato B, Sambiasi D, Porcelli L, Guida G, Mattioli E, Paradiso A, Merla G, Micale L et al (2014) Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. Cell Death Dis 5:e1076
29. Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W (2011) PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat 127(3):861–869
30. Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W (2011) Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch 458(1):55–64
31. Frizzell K, Kraus WL (2009) PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2? Breast Cancer Res 11(6):111
32. Green A, Caracappa D, Benhasouna A, Alshareeda A, Nolan C, Macmillan RD, Madhusudan S, Ellis I, Rakha E (2014) Biological and clinical significance of PARP1 protein expression in breast cancer. Breast Cancer Res Treat 1–10
33. Erener S, Pétrilli V, Kassner I, Minotti R, Castillo R, Santoro R, Hassa PO, Tschopp J, Hottiger MO (2012) Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF-κB target genes. Mol Cell 46(2):200–211
34. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM, Baer R (1996) Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14(4):430–440
35. Daley JM, Kwon Y, Niu H, Sung P (2013) Investigations of homologous recombination pathways and their regulation. Yale J Biol Med 86(4):453–461
36. Cousineau I, Abaji C, Belmaaza A (2005) BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis. Cancer Res 65(24):11384–11391
37. Sun C, Li N, Yang Z, Zhou B, He Y, Weng D, Fang Y, Wu P, Chen P, Yang X et al (2013) miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst 105:1750–1758
38. Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S, Sodha N, Bancroft E, Fletcher A, Cooper C et al (2009) Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology 55(6):696–704
39. Söderlund K, Skoog L, Fornander T, Askmalm MS (2007) The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer. Radiother Oncol 84(3):242–251
40. Davies AA, Masson J-Y, McIlwraith MJ, Stasiak AZ, Stasiak A, Venkitaraman AR, West SC (2001) Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7(2):273–282
41. Zakhartseva LM, Gorovenko NG, Podolskaya SV, Anikusko NF, Lobanova OE, Pekur KA, Kropelnytskyi VA, Shurygina OV (2009) Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations. Exp Oncol 31(3):174–178
42. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29(4):418–425
43. Holstege H, Joosse SA, van Oostrom CTM, Nederlof PM, de Vries A, Jonkers J (2009) High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 69(8):3625–3633
44. Alshareeda AT, Negm OH, Albarakati N, Green AR, Nolan C, Sultana R, Madhusudan S, Benhasouna A, Tighe P, Ellis IO et al (2013) Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. Breast Cancer Res Treat 139(2):301–310
45. De Summa S, Pinto R, Sambiasi D, Petriella D, Paradiso V, Paradiso A, Tommasi S (2013) BRCAness: a deeper insight into basal-like breast tumors. Ann Oncol 24(Suppl 8):viii13–viii21
46. Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4(10):814–819
47. Dedes KJ, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS (2011) Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. (1551-4005 (Electronic)). Cell Cycle 10:1192–1199